Daily Market BriefHealthcare

Big Pharma Earnings Beat; GLP-1 Expansion Continues

Bristol Myers, Regeneron, and DexCom raised guidance after Q2 beats; Lilly invests $750M in US manufacturing capacity

Money365.Market AI
3 min read
Market MoodRisk-On
Sentiment+68Bullish

Key DriverStrong quarterly earnings beats across major pharma and medtech names drove sector optimism with raised full-year guidance

Today in 30 Seconds

  • Bristol Myers posted Q2 beat, growth portfolio now 60% of revenue with Eliquis up 21%
  • Regeneron revenue surged 17% to $4.3B on 38% Dupixent growth, 52% EYLEA HD rise
  • J&J secured FDA clearance for surgical robot, targeting $100B revenue milestone

Top Movers

$BMY▲ +12.6%

Bristol Myers Squibb

Q2 earnings beat with raised FY guidance

$REGN▲ +36.1%

Regeneron Pharmaceuticals

Record Dupixent sales up 38%, 12-month performance

All Briefs

Big Pharma & Biotech

Bullish

Bristol Myers Growth Portfolio

60%+of revenue

Eliquis Revenue Growth

21%+YoY

Regeneron Q2 Revenue

$4.3B+17%

Dupixent Sales Growth

38%+YoY

Lilly Manufacturing Investment

$750Mexpansion
$BMY$REGN$LLY

Bristol Myers Squibb ($BMY) reported second-quarter results that exceeded Wall Street expectations, with management raising full-year guidance for both revenue and earnings per share. The company's growth portfolio now drives 60% of total revenue, powered by a 21% surge in $BMY's anticoagulant Eliquis. Shares posted a 12.57% one-month return and 21.32% year-to-date gain following the earnings beat.

Regeneron Pharmaceuticals ($REGN) delivered 17% revenue growth with total quarterly sales reaching $4.3 billion, fueled by record Dupixent sales that jumped 38% and EYLEA HD posting a 52% increase. The company has gained 36.1% over the past 12 months as it navigates competitive pressures while advancing a deep pipeline.

Eli Lilly ($LLY) and Resilience announced a $750 million investment to increase US medicines production, supporting advanced manufacturing operations in Cincinnati as the next wave of GLP-1 drugs expands beyond obesity treatment.

MedTech & Devices

Bullish

DexCom Q2 Revenue

$1.31B+13%

J&J Revenue Target

$100Bmilestone

Thermo Fisher 30-day Return

15.04%+recent
$DXCM$JNJ$TMO

DexCom ($DXCM) reported second-quarter revenue of $1.31 billion, representing 13% growth year-over-year, and raised full-year profitability guidance driven by strong international performance and margin expansion. The continuous glucose monitoring company beat earnings estimates with improved operational efficiency.

Johnson & Johnson ($JNJ) received FDA clearance for its surgical robot, hiked its dividend for the 64th consecutive time, and is targeting $100 billion in revenue as the pharmaceutical and medical device giant expands its presence in surgical robotics.

Thermo Fisher Scientific ($TMO) exceeded second-quarter market expectations with broad-based demand and fresh regulatory clearances across its diagnostics portfolio, posting a 15.04% 30-day share price return and 22.92% 90-day gain.

Health Insurance & Managed Care

Bullish

Cigna Q2 Revenue

$71B+beat expectations
$CI

Cigna Group ($CI) raised its full-year 2026 adjusted earnings outlook after reporting second-quarter results that exceeded expectations in both its Evernorth health services business and Cigna Healthcare insurance segment. The company reported second-quarter total revenue of $71 billion, with management highlighting outperformance across both core operating units.

Corporate Actions & Capital Deployment

Neutral

Amgen Q3 Dividend

$2.52per share
$AMGN

Amgen ($AMGN) announced its Board of Directors declared a $2.52 per share dividend for the third quarter of 2026, payable September 11 to stockholders of record as of August 21. The company also launched the first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad, bringing the undergraduate summer research program to India for the first time.

Looking Ahead

Neutral
$LLY$JNJ$ISRG

The healthcare sector faces continued focus on GLP-1 drug expansion beyond obesity treatment, with analysts comparing prospects for $LLY versus Novo Nordisk as the blockbuster class shatters sales records. Surgical robotics competition intensifies following $JNJ's FDA clearance, while Intuitive Surgical ($ISRG) has declined 37% year-to-date despite revenue growth, with analysts reassessing valuation levels. Continued quarterly earnings momentum from diagnostic and monitoring device makers suggests sustained demand for healthcare technology solutions heading into the second half of 2026.

What to Watch

Sep 11

Amgen Q3 dividend payment ($2.52/share)

$AMGN
Low

Risk Flags

NoteGLP-1 market expansion attracting new competitors, intensifying pricing pressure
NoteSurgical robotics market seeing increased competition with J&J FDA clearance

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy

Back to All Briefs